RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Soleno Therapeutics Stock

Soleno Therapeutics ROE 2024

Soleno Therapeutics ROE

-0.25

Ticker

SLNO

ISIN

US8342032005

WKN

A2JSTG

In 2024, Soleno Therapeutics's return on equity (ROE) was -0.25, a -89.36% increase from the -2.33 ROE in the previous year.

Soleno Therapeutics Aktienanalyse

What does Soleno Therapeutics do?

Soleno Therapeutics Inc is a biopharmaceutical company focused on rare diseases and unmet medical needs. The company was founded in 1999 and is headquartered in Redwood City, California. Soleno Therapeutics develops and markets innovative therapies for patients who have previously had limited or no treatment options. Business model: Soleno Therapeutics specializes in developing therapies for rare diseases. The company takes an innovative approach and utilizes cutting-edge technologies to develop drugs that have the potential to improve the lives of affected patients. The company works closely with leading research institutions and experts in the industry and invests significantly in research and development of new therapies. The company employs a two-pronged approach, developing innovative drugs for unmet medical needs while also acquiring already approved drugs and optimizing them for new applications. Soleno Therapeutics then markets these drugs to physicians, hospitals, and patients worldwide. Segments: Soleno Therapeutics specializes in developing therapies for rare diseases, focusing on three main segments: 1. Hypophosphatasia: Hypophosphatasia is a rare metabolic disorder that leads to the accumulation of phosphate in the bones and tissues. This results in weak bones, pain, and a variety of other symptoms. Soleno Therapeutics has developed a novel enzyme replacement therapy product that aims to support bone formation and alleviate the symptoms of the disease. 2. Prader-Willi Syndrome: Prader-Willi Syndrome is a rare genetic disorder characterized by obesity, mental retardation, and hormonal imbalances. Soleno Therapeutics has developed a product that suppresses hunger, helping patients develop a normal diet and achieve a healthy weight. 3. Other indications: Soleno Therapeutics is also working on developing therapies for other rare diseases and unmet medical needs, including conditions such as hemophilia, narcolepsy, and Parkinson's. Products: Soleno Therapeutics currently offers the following products: 1. Treakisym: Treakisym is a novel enzyme replacement therapy product aimed at supporting bone formation in patients with hypophosphatasia. The medication has already been approved in Japan. 2. Solinum: Solinum is a product that suppresses hunger in patients with Prader-Willi Syndrome. The medication is currently in Phase III of clinical trials and is expected to be approved in the coming years. 3. Other products: Soleno Therapeutics also has a range of other products in the pipeline, focusing on the development of therapies for rare diseases. Conclusion: Soleno Therapeutics is an innovative biopharmaceutical company specializing in the development of therapies for rare diseases and unmet medical needs. The company invests significantly in research and development of new medications and works closely with industry experts. Soleno Therapeutics has already launched an enzyme replacement therapy product for hypophosphatasia and is currently working on the approval of a hunger suppressant product for Prader-Willi Syndrome. The company also has a range of other medications in the pipeline, aiming to improve the lives of patients with rare diseases. Soleno Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROE Details

Decoding Soleno Therapeutics's Return on Equity (ROE)

Soleno Therapeutics's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Soleno Therapeutics's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Soleno Therapeutics's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Soleno Therapeutics’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Soleno Therapeutics stock

What is the ROE (Return on Equity) of Soleno Therapeutics this year?

The ROE of Soleno Therapeutics this year is -0.25 undefined.

How has the Return on Equity (ROE) of Soleno Therapeutics developed compared to the previous year?

The ROE of Soleno Therapeutics has increased by -89.36% decreased compared to the previous year.

What impact does a high ROE (Return on Equity) have on investors of Soleno Therapeutics?

A high ROE indicates that Soleno Therapeutics generates good returns on capital and is successful in monetizing its investments. This is a positive indicator for investors.

What impact does a low ROE (Return on Equity) have on investors of Soleno Therapeutics?

A low ROE can indicate that Soleno Therapeutics is having difficulties monetizing its investments successfully and can be a negative signal for investors.

How does a change in the ROE (Return on Equity) of Soleno Therapeutics affect the company?

A change in ROE (Return on Equity) of Soleno Therapeutics can be an indicator of the financial performance of the company and demonstrate how successful the company is compared to other companies in the same industry.

How to calculate the ROE (Return on Equity) of Soleno Therapeutics?

The ROE (Return on Equity) is calculated by dividing the company's profit by the total equity. The formula is: ROE = Profit / Total equity.

Which factors influence the ROE (Return on Equity) of Soleno Therapeutics?

Some factors that can influence Soleno Therapeutics's Return on Equity (ROE) include the efficiency in using equity, the profitability of the company, and the financing structure.

What strategic measures can take to improve the ROE (Return on Equity)?

To improve the Return on Equity (ROE), can take measures such as cost savings, increasing revenue, improving efficiency in the use of equity, and making changes in the financing structure. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to improve ROE.

How much dividend does Soleno Therapeutics pay?

Over the past 12 months, Soleno Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Soleno Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Soleno Therapeutics?

The current dividend yield of Soleno Therapeutics is .

When does Soleno Therapeutics pay dividends?

Soleno Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Soleno Therapeutics?

Soleno Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Soleno Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Soleno Therapeutics located?

Soleno Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Soleno Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Soleno Therapeutics from 9/27/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/27/2024.

When did Soleno Therapeutics pay the last dividend?

The last dividend was paid out on 9/27/2024.

What was the dividend of Soleno Therapeutics in the year 2023?

In the year 2023, Soleno Therapeutics distributed 0 USD as dividends.

In which currency does Soleno Therapeutics pay out the dividend?

The dividends of Soleno Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Soleno Therapeutics

Our stock analysis for Soleno Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Soleno Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.